請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37008完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Jhih-Wei Jian | en |
| dc.contributor.author | 簡志偉 | zh_TW |
| dc.date.accessioned | 2021-06-13T15:17:49Z | - |
| dc.date.available | 2013-08-08 | |
| dc.date.copyright | 2008-08-08 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-24 | |
| dc.identifier.citation | 1.Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
2.Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231-6. 3.Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172-9. 4.Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-86. 5.Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001;34:194-203. 6.Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005;34 Suppl 1:S15-21. 7.Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004;39:51-7. 8.Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:160-70. 9.Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57. 10.Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005;42:813-9. 11.Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005;42:480-5. 12.Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003;278:591-607. 13.Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002;37:855-62. 14.Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996;98:1185-94. 15.Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8. 16.Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008;134:1470-81. 17.Guidotti LG, Chisari FV. Cytokine-induced viral purging--role in viral pathogenesis. Curr Opin Microbiol 1999;2:388-91. 18.Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130:823-37. 19.Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004;127:1356-71. 20.Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102-10. 21.Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-7. 22.Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001;34:447-54. 23.Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6. 24.Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006;106:1326-30. 25.Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006;44:39-46. 26.Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. 'Occult' hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142-6. 27.Datta S, Banerjee A, Chandra PK, Chowdhury A, Chakravarty R. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers. J Med Virol 2006;78:53-9. 28.Saito T, Shinzawa H, Uchida T, Kawamata O, Honma S, Watanabe H, et al. Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B. J Med Virol 1999;58:325-31. 29.Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-64. 30.Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17:71-91. 31.Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29:106-12. 32.Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72. 33.Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. 34.Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81. 35.Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-29. 36.Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-73. 37.Chang HC, Yu MW, Lu CF, Chiu YH, Chen CJ. Risk factors associated with hepatitis C virus infection in Taiwanese government employees. Epidemiol Infect 2001;126:291-9. 38.Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology 2004;126:347-50. 39.Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68. 40.Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000;32:626-9. 41.Potash JB, Willour VL, Chiu YF, Simpson SG, MacKinnon DF, Pearlson GD, et al. The familial aggregation of psychotic symptoms in bipolar disorder pedigrees. Am J Psychiatry 2001;158:1258-64. 42.Chen WJ, Liu PH, Ho YY, Chien KL, Lo MT, Shih WL, et al. Sibling recurrence risk ratio analysis of the metabolic syndrome and its components over time. BMC Genet 2003;4 Suppl 1:S33. 43.Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31. 44.Yu MW, Chang HC, Chen PJ, Liu CJ, Liaw YF, Lin SM, et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002;31:1008-15. 45.Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-71. 46.Tong MJ, Weiner JM, Ashcavai MW, Vyas GN. Evidence for clustering of hepatitis B virus infection in families of patients with primary hepatocellular carcinoma. Cancer 1979;44:2338-4. 47.Szmuness W, Prince AM, Hirsch RL, Brotman B. Familial clustering of hepatitis B infection. N Engl J Med 1973;289:1162-6. 48.Tai DI, Changchien CS, Hung CS, Chen CJ. Replication of hepatitis B virus in first-degree relatives of patients with hepatocellular carcinoma. Am J Trop Med Hyg 1999;61:716-9. 49.Porres JC, Carreno V, Bartolome J, Gutiez J, Castillo I. A dynamic study of the intrafamilial spread of hepatitis B virus infection: relation with the viral replication. J Med Virol 1989;28:237-42. 50.Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889-93. 51.Hsieh CC, Tzonou A, Zavitsanos X, Kaklamani E, Lan SJ, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study. Am J Epidemiol 1992;136:1115-21. 52.Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8. 53.Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107. 54.Kidd-Ljunggren K, Holmberg A, Blackberg J, Lindqvist B. High levels of hepatitis B virus DNA in body fluids from chronic carriers. J Hosp Infect 2006;64:352-7. 55.van der Eijk AA, Niesters HG, Gotz HM, Janssen HL, Schalm SW, Osterhaus AD, et al. Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol 2004;29:92-4. 56.Gupta S, Gupta R, Joshi YK, Singh S. Role of horizontal transmission in hepatitis B virus spread among household contacts in north India. Intervirology 2008;51:7-13. 57.Craxi A, Tine F, Vinci M, Almasio P, Camma C, Garofalo G, et al. Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk. Am J Epidemiol 1991;134:641-50. 58.Toukan AU, Sharaiha ZK, Abu-el-Rub OA, Hmoud MK, Dahbour SS, Abu-Hassan H, et al. The epidemiology of hepatitis B virus among family members in the Middle East. Am J Epidemiol 1990;132:220-32. 59.Whittle H, Inskip H, Bradley AK, McLaughlan K, Shenton F, Lamb W, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990;161:1112-5. 60.Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 1998;147:478-87. 61.Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet 2005;365:638-40. 62.Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-7. 63.Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007;132:1955-67. 64.Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33. 65.Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006;36 Suppl 1:S33-44. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37008 | - |
| dc.description.abstract | 研究背景：肝細胞癌（hepatocellular carcinoma；HCC）病例家族是B型肝炎病毒感染的高危險性族群，本研究目的在於調查HCC家族B型肝炎隱性感染的家族聚集程度，及探討B型肝炎隱性感染的臨床表徵。材料與方法：研究個案來自兩個來源：HBsAg陽性之HCC指標病例一等親共601名HBsAg陰性個案，他們來自251個家族；另一個是來自公務人員世代所選取的602名HBsAg陰性個案做為對照組，對照組和HCC指標病例親屬在年齡上配對。我們採用Nested PCR偵測 HBV X 和Core基因區，X基因區可測得HBV DNA者，才進一步分析Core 基因區。B型肝炎病毒隱性感染的定義為X基因區可測得HBV DNA者。對於隱性感染者，進一步使用Real time PCR測量病毒量。結果：HCC家族B型肝炎隱性感染盛行率(26.0%)顯著高於對照組(18.4%)(P=0.0017)，且具有顯著家族聚集(corrected familial recurrence risk ratio:2.59)。和家族內隱性感染正相關的因子包括anti-HCV陽性(P=0.0332)、HCC指標病例為女性(P=0.0433)、及家中HBsAg人數( P trend=0.0414)。對Core和X基因區皆可測得者的HBV DNA濃度顯著高於只有X基因區可測得者（P<0.0001）。ALT/AST異常及肝臟實質病變（由超音波測量)的危險性隨無隱性感染、只有X基因區可測得者、X和Core基因區皆可測得者漸增，對於X和Core基因區皆可測得者和無隱性感染者比較，OR (95% CI) 對於ALT異常、AST異常和肝臟實質病變，分別為5.31 (95%CI=2.66-10.60)、4.15 (95%CI=2.10-8.24)、和2.19 (95%CI=1.40-6.06)。結論：HCC病例家族中有B型肝炎隱性感染的家族聚集。B型肝炎隱性感染可能導致肝臟疾病。 | zh_TW |
| dc.description.abstract | Background & Aims: Taiwan is an endemic area of hepatitis B virus (HBV) infection. This study aimed to assess the extent to which occult HBV infection aggregates in families with HCC, and to determine the association between occult HBV infection and hepatic abnormalities. Material and Methods: Study subjects consisted of 601 HBsAg-negative first-degree relatives from 251 families with HCC and 602 HBsAg-negative, age-matched unrelated individuals as controls. Occult HBV infection was defined by the detection of HBV DNA in serum by PCR amplification assay on the X region of HBV. PCR assay on core region was performed in subjects who showed positivity in X region. Results: Occult HBV infection was detected in 26.0% of relatives from families with HCC and in 18.4% of controls (P=0.0017). The familial recurrence risk ratio for occult HBV infection was 2.59. Anti-HCV positivity, female gender of HCC proband, and number of HBsAg-positive relatives in a family were positively associated with an increased likelihood of occult HBV infection. Circulating HBV DNA was higher in relatives who showed positivity in both X and core regions than in those who showed positivity in the X region only (P<0.0001). The presence of occult HBV was associated with elevated ALT (odds ratios were 2.01 [95% CI: 1.06-3.80] and 5.31 [2.66-10.60], respectively, for positivity for X region and both X and core regions), irrespective of age, sex, alcohol drinking, and anti-HCV status. Conclusions: There is familial aggregation of occult HBV infection in families with HCC. Occult HBV infection may increase risk of hepatic abnormalities. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T15:17:49Z (GMT). No. of bitstreams: 1 ntu-97-R95842019-1.pdf: 1159183 bytes, checksum: e6602c31b0a6ff5d018045865424fb71 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 致謝…………………………………………………………………i
中文摘要……………………………………………………………ii 英文摘要……………………………………………………………iii 目錄…………………………………………………………………v 表目錄………………………………………………………………vi 研究背景……………………………………………………………1 材料與方法…………………………………………………………4 結果…………………………………………………………………9 討論…………………………………………………………………12 參考文獻……………………………………………………………16 附錄…………………………………………………………………28 | |
| dc.language.iso | zh-TW | |
| dc.subject | 臨床特徵 | zh_TW |
| dc.subject | B型肝炎病毒隱性感染 | zh_TW |
| dc.subject | 肝細胞癌家族 | zh_TW |
| dc.subject | 家族聚集 | zh_TW |
| dc.subject | 半巢式聚合酵素鏈鎖反應 | zh_TW |
| dc.subject | Occult hepatitis B virus infection | en |
| dc.subject | Clinical Features | en |
| dc.subject | Semi-Nested PCR | en |
| dc.subject | Familial aggregation | en |
| dc.subject | Families with Hepatocellular Carcinoma | en |
| dc.title | B型肝炎病毒隱性感染在肝細胞癌家族之盛行率及臨床特徵 | zh_TW |
| dc.title | Prevalence and Clinical Features of Occult Hepatitis B Virus Infection in Families with Hepatocellular Carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 葉昭廷(Chau-Ting Yeh),劉俊人(Chun-Jen Liu),劉信孚(Hsin-Fu Liu) | |
| dc.subject.keyword | B型肝炎病毒隱性感染,肝細胞癌家族,家族聚集,半巢式聚合酵素鏈鎖反應,臨床特徵, | zh_TW |
| dc.subject.keyword | Occult hepatitis B virus infection,Families with Hepatocellular Carcinoma,Familial aggregation,Semi-Nested PCR,Clinical Features, | en |
| dc.relation.page | 31 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-07-25 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 1.13 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。